$2.14
+0.03 (+1.42%)
Open$2.10
Previous Close$2.11
Day High$2.21
Day Low$2.09
52W High$3.19
52W Low$1.32
Volume—
Avg Volume1.42M
Market Cap214.32M
P/E Ratio34.16
EPS$0.06
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+1,358.4% upside
Current
$2.14
$2.14
Target
$31.21
$31.21
$17.92
$31.21 avg
$31.70
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 44.97M | 40.27M | 361.03M |
| Net Income | 2.47M | 1.99M | 15.50M |
| Profit Margin | 5.5% | 5.2% | 4.3% |
| EBITDA | 4.40M | 3.74M | 29.24M |
| Free Cash Flow | — | — | 6.36M |
| Rev Growth | +11.7% | +11.7% | +17.6% |
| Debt/Equity | — | — | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |